Presenting our latest manuscript out now in @SpringerNature@LeukemiaJnl exploring the biology around RUNX1 aberrations in blast-phase CML.
We've discovered the RBP SPATS2L is induced by RUNX1 loss impacting CML growth, survival and chemosensitivity
https://t.co/zzDIZwMLt4
1/5
How does leukaemia develop? 🩸 How long does it take? ⏳
🌟 Our paper, started back when I was a PhD student in @jrblundell’s lab, is out today in @Nature 🌟
Yearly blood samples from women who developed AML in later life let us trace it back decades 👇
https://t.co/fqyOpc5OKH
We are now less than a week away from the start of WntUK 2026 at the @CRUK_SI in Glasgow!
Drs Nadia Nasreddin, Kieran Hodson & David Willnow, and CRUK SI team have put together an amazing 2-day programme which promises to be the best WntUK meeting yet.
https://t.co/9WOFBGz02Q
We've a 4-year PhD investigating the role of Wnt/β-catenin signalling in viral entry advertised through the Wessex One Health Doctoral Landscape Award (scroll to 'Projects' under @SussexUni).
Deadline 12.00, 11/01/2027. More info and application below👇
https://t.co/IyWLyu9683
Ho ho what fun we had today…..
Pleasure hosting @bloodcancer_uk in our labs to support the big @BloodCancer_Res Christmas campaign.
Look out for ‘Double the Impact’ and all it means for life saving blood cancer research, coming soon…..
🕯️ 🧫🌲 🔬 🎄🧬🎅🥼🤶🧪🧑🎄🎍
Pleased to accept an invitation to join the Editorial board of @Cellpress@MolTherapy Oncology as an Associate Editor.
Looking forward to reviewing the latest cutting edge studies in translational/molecular cancer research.
https://t.co/YUYVONo3HU
@ASH_hematology 2026 annual meeting abstracts are out!
Well done David Palmer and Sophie Kellaway on their oral abstract on RUNX1 frameshift mutations in AML.
Visit MCCNO - Hall C on Sat 12 Dec to see the oral abstract highlight of the meeting! 👏👏👏
https://t.co/9u5oJIWCC8
DNA2 is an emerging anti-cancer target. We describe a workflow for DNA2 inhibitor discovery and highlight that currently used commercial DNA2i have an off-target effect on DNA synthesis, while we find no evidence of effective DNA2 inhibition in cells. https://t.co/udxSuqwK09
https://t.co/AYFHTLOfAu
Interested in a PhD?- are you a medical student? TP53-mutant acute erythroid leukaemia is among the most difficult cancers to treat and may rely on surrounding cells for survival.
Just one week remaining before the FlexCAT MSCA-DTP closes.
Beat the ghosts and ghouls to halloween and get your PhD applications in before October 31st!
🎃👻💀🪦🧟♂️
Just one week remaining before the FlexCAT MSCA-DTP closes.
Beat the ghosts and ghouls to halloween and get your PhD applications in before October 31st!
🎃👻💀🪦🧟♂️
Today in @Nature we present the development and characterisation of the first-in-class catalytic inhibitor of METTL1 as a new therapeutic strategy against solid and blood cancers.
Another flagship collaboration between my lab @SCICambridge@Cambridge_Haem (@Cambridge_Uni) and @storm_tx, co-led by my brilliant colleague @OliverRausch and driven by Eliza Yankova, Alexandra Sapetschnig and Beth Thomas.
A big thank you to the long list of authors who participated in this study and provided their critical input and diverse expertise. I am also very thankful and lucky to have the continuous support of @wellcometrust, @LeukUK and @CR_UK.
https://t.co/jODFOc9kDq
📰 New network publication! 🗞️
Congrats to Prof @andrea_pepper2, Dr Emma Kennedy and team in @BSMSMedSchool for their publication in @ASH_hematology@BloodPortfolio.
Study identifies distinct CLL subgroups and assays for predicting BTKi sensitivity. 👊
https://t.co/NqzQL0uUOK
Incoming inaugural Professorial lecture!
Professor @SiFTW from @BSMSMedSchool will be giving his inaugural professorial lecture on Thurs 19/11.
Simon will explore how computer simulations could help predict cancer progression and identify the best treatments. Booking info 👇
Just one week remaining before the FlexCAT MSCA-DTP closes.
Beat the ghosts and ghouls to halloween and get your PhD applications in before October 31st!
🎃👻💀🪦🧟♂️
🔔 Under a month until the flexCAT PhD deadline on Oct 31st ⏰
Join the best & brightest in this @EU_Commission funded MSCA-DTP to tackle oncogenic B-catenin
Apply via @MedUniGraz for our project DC14 here at @SussexUni@BiochemBiomedUS@SussexLifeSci
https://t.co/6LrAyJFNrA